Angela Scheuerle
Pediatrics · Dallas, TXNPI 1073570586
Payments from drug & device makers
Across 705 payments — averaging $187.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$56K
- AbbVie$22K
- Sanofi US Services Inc.$14K
- UCB Biosciences Inc.$6K
- Viiv Healthcare Company$6K
- Merck$6K
- plus $22K from 18 others
Across 410 payments — averaging $197.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Lupin Inc.$30K
- Novo Nordisk AS$17K
- Teva Pharmaceuticals USA, Inc.$6K
- UCB, Inc.$5K
- Mylan Inc.$4K
- F. Hoffmann-la Roche AG$4K
- plus $15K from 9 others
What the payments were for
- Consulting fees$113,52297%
- Speaking & faculty fees$1,8462%
- Grants$7181%
- Travel & lodging$8611%
- Food & beverage$5700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 70 | $56,250 |
| AbbVie | 104 | $22,247 |
| Sanofi US Services Inc. | 20 | $13,794 |
| UCB Biosciences Inc. | 6 | $6,125 |
| Viiv Healthcare Company | 49 | $5,837 |
| Merck | 100 | $5,691 |
| Hikma Pharmaceuticals USA | 73 | $4,381 |
| Boehringer Ingelheim | 80 | $4,270 |
| Amneal Pharmaceuticals LLC | 59 | $3,889 |
| Roche Products Limited | 2 | $3,250 |
| Sandoz | 42 | $1,944 |
| Mylan Inc. | 34 | $1,438 |
| F. Hoffmann-la Roche AG | 13 | $990 |
| Gilead | 20 | $964 |
| Zydus Pharmaceuticals (USA) Inc. | 12 | $528 |
| Lupin Inc. | 6 | $288 |
| GSK | 2 | $180 |
| Sanofi | 4 | $112 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $106 |
| PTC Therapeutics, Inc. | 1 | $28 |
| Orchard Therapeutics North America | 1 | $26 |
| Sentynl Therapeutics, Inc. | 1 | $24 |
| Biomarin Pharmaceutical Inc. | 1 | $13 |
| Travere Therapeutics, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Norvir$17,973
- TIVICAY$3,250
- Zidovudine$2,190
- ISENTRESS$1,257
- DELSTRIGO$1,257
- PIFELTRO$1,257
- AUBAGIO$1,089
- LEMTRADA$1,089
- CRIXIVAN$1,020
- Fuzeon$517
- Invirase$517
- NEVIRAPINE$479
- Abacavir Sulfate$479
- GENERIC$107
- BOSENTAN$107
How this compares
$132,384 in reported general payments places this provider in the 95th percentile of 5,361 pediatrics providers in Texas.
Other pediatrics in Dallas
- Ronald BlairDallas$7.7M
- Marcial Oquendo RinconDallas$1.7M
- Rohan MenonDallas$119K
- Ralph DeberardinisDallas$56K
- Kashif AliHouston$19.1M
- Clifford YutThe Woodlands$10.2M
- Ionela IacobasHouston$10.1M
- Khozema PalanpurwalaHouston$9.7M
- Robert BellBeaumont$9.3M
- John ClintonPort Lavaca$8.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.